New paradigm for treating dry eye needed to overcome ‘failures’

Article

Dry eye is the most common reason why patients seek help from optometrists and ophthalmologists. It is also a leading cause of intolerance for contact lens users and the discontinuation of their use. However, a new paradigm is needed for “confronting and overcoming failures” in treating ocular surface disease.

 

Seattle-Dry eye is the most common reason why patients seek help from optometrists and ophthalmologists. It is also a leading cause of intolerance to contact lens users and the discontinuation of their use. However, a new paradigm is needed for “confronting and overcoming failures” in treating ocular surface disease.

At an education session held at the annual meeting of the American Academy of Optometry, Donald Korb, OD, a Boston-based researcher and optometrist and chief technical officer of TearScience Inc., outlined why a new paradigm is needed. TearScience is a company dedicated to the restorative treatment of evaporative dry eye.

Recently, there has been a change in the direction of the prevailing views regarding dry eye. A 2011 workshop changed the paradigm-both for the prevailing views of etiology and treatment-from the traditional aqueous and mucous-based models for dry eye to the inclusion and emphasis of meibomian gland dysfunction (MGD), Dr. Korb explained. MGD is chronic, prevalent, and progressive, and will not “go away unless the root cause goes away.”

‘Lipid deficiency and evaporative stress underlie the dye eye cascade,” said Dr. Korb.

In his presentation, he discussed the current treatments as well as his own new model for the "Dry Eye Cascade," a proposed a mechanism of action for how minimal hypsecretory MGD, which is frequently not obvious, can cascade into a number of negative changes in the eye.

“It is important for patients to understand that dry eye is just not a matter of going to the drug store to get drops,” he said.

Treatments need to be both palliative and restorative, and include both home and professional-based modalities. These include lipid eye drops and sprays, warm compresses, blinking exercises, self-expression, and new treatments, such as the Lipiflow Thermal Pulsation System, which has received FDA approval.

Dr. Korb, who is the inventor and patent holder of Lipiflow, explained that its role is to liquefy, express and evacuate ductal obstruction and gland contents. It only takes 12 minutes and it is painless for the patient.

Newsletter

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

Recent Videos
Devin Sasser, OD, shares his excitement for Acuvue Oasys MAX 1-Day multifocal for astigmatism, the first and only daily disposable multifocal toric contact lens.
Reviewing the State of Dry Eye Survey with Selina McGee, OD, FAAO, Dipl ABO
Jessilin Quint, OD, MBA, FAAO, outlines her AOA's Optometry's Meeting 2025 presentation on nutrition and its impact on ocular health.
Carolyn Majcher, OD, FAAO, detailed a talk she gave alongside Mary Beth Yackey, OD, at Optometry's Meeting 2025.
Shelby Brogdon, OD, details opportunities for practices to answer the patient's concerns from the chair before they hit the internet for their contact lens needs.
Christi Closson, OD, FAAO, shares her excitement for the new Acuvue Oasys MAX 1-Day multifocal for astigmatism
Karen R. Hoffman, OD, shares how customizable scleral lenses can transform vision for patients with complex corneas, achieving 20/20 outcomes and enhanced comfort.
Janna Pham, OD, shares key takeaways from a corneal tomography session she presented alongside Travis Pfeifer, OD; and Matthew McGee, OD.
Jacob Lang, OD, FAAO, details early symptom relief demonstrated in as early as day 1 during AOA's Optometry's Meeting 2025.
When Langis Michaud, OD, MSc, FAAO, FSLS, FBCLA, FEAOO, began fitting scleral lenses 20 years ago, there was limited knowledge about conjunctival characteristics, scleral shape, and lens behavior.
© 2025 MJH Life Sciences

All rights reserved.